

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Peer Review Meeting.

*Date:* February 26, 2016.

*Time:* 1:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Room 3C100, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Brenda L. Fredericksen, Ph.D., Assistant Professor, Scientific Review Program, Division of Extramural Activities, Room # 3G22A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5052, [brenda.fredericksen@nih.gov](mailto:brenda.fredericksen@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: January 29, 2016.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016–02051 Filed 2–3–16; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### The National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning: Draft Strategic Research Priorities; Request for Comments

**SUMMARY:** The National Heart, Lung, and Blood Institute (NHLBI) is soliciting comments from the public on its Draft Strategic Research Priorities, which will help inform Institute-solicited research

activities over the next decade. The draft document is available through the NHLBI Strategic Visioning Web site (<https://www.nhlbi.nih.gov/about/documents/strategic-visioning/public-comment-period>).

**DATES:** To ensure consideration, written comments must be received by March 7, 2016.

**ADDRESSES:** The Draft Strategic Research Priorities can be viewed here: (<https://www.nhlbi.nih.gov/about/documents/strategic-visioning/public-comment-period>). Please email comments to [NHLBI\\_Vision@mail.nih.gov](mailto:NHLBI_Vision@mail.nih.gov). Email comments are preferred, but comments may also be submitted by regular mail to: NHLBI Office of the Director, Attn: Strategic Visioning Team, National Heart, Lung, and Blood Institute, Building 31, Room 5A48, 31 Center Drive MSC 2486, Bethesda, MD 20892.

**FOR FURTHER INFORMATION CONTACT:** Dana Camak, Executive Assistant, Office of Science Policy, Engagement, Education, and Communications at the National Heart, Lung, and Blood Institute, NIH, 31 Center Dr., Building 31, Room 4A10, Bethesda, MD 20892–2480. Telephone: 301–496–4236. Email: [NHLBI\\_Vision@mail.nih.gov](mailto:NHLBI_Vision@mail.nih.gov). Additional information may be obtained at <https://www.nhlbi.nih.gov/about/documents/strategic-visioning/public-comment-period>.

#### SUPPLEMENTARY INFORMATION:

##### Background

For more than 60 years, the NHLBI has supported research to reduce the burden of heart, lung, blood, and sleep disorders and diseases. For example, long-term research investments in cardiovascular basic, clinical and population sciences have contributed to a 78% decrease in death rates due to coronary heart disease, a greater understanding of the complexity of chronic lung disease, and to an increase in life expectancy for persons with sickle cell disease from 14 years to 40–60 years. However, heart, lung, and blood diseases remain leading causes of death for American men and women, and we face ongoing health challenges such as an aging population, rising health care costs, and continued gender and racial disparities.

Over the last year, NHLBI has been engaged in a Strategic Visioning process that engages the NHLBI community to inform Institute-solicited research activities. The goals for the Strategic Visioning process span the NHLBI mission and include research on health and disease in heart, lung, blood, and sleep systems; the translation of research for prevention, diagnosis, and

treatment of diseases; and the support of training and resources for biomedical researchers across the landscape.

The strength of the NHLBI's Strategic Visioning process rests in the collective input of the diverse perspectives within the heart, lung, blood, and sleep community, including, but not limited to, scientists, academic institutions, patient communities, and the general public, allowing these stakeholders the opportunity to identify and catalyze areas where targeted investments are needed. In spring of 2015, the community identified scientific opportunities (Compelling Questions, or CQs) and barriers to research progress (Critical Challenges, or CCs) facing heart, lung, blood, and sleep research. NHLBI leadership, staff, and advisory groups reviewed the ideas to identify the highest priorities for the Institute based on timeliness, feasibility, and overall ability to advance the fields of study.

Ultimately, more than 1,000 ideas were submitted to the Strategic Visioning Forum. Ideas came from all 50 states and from countries across the globe, representing diverse perspectives of scientists, academic institutions, patient communities, and the general public.

Together the NHLBI, its Board of Extramural Experts, and the NHLBI Advisory Council, refined and synthesized the CQs and CCs as appropriate, and organized them under Objectives. The resulting CQs and CCs, as delineated in the Draft Strategic Research Priorities document, address important research avenues and support the Institute's strategic goals. The Draft Strategic Research Priorities document is not meant to encompass NHLBI's entire research portfolio, but instead is meant to reflect those areas of study that are currently deemed to be the most important, timely, and feasible for the Institute to address in its targeted/solicited research portfolio in the next decade.

#### Request for Comments

This notice invites public comment on NHLBI's Draft Strategic Research Priorities. We seek diverse perspectives including, but not limited to, that of patients, patient advocates, clinicians, and researchers, as well as federal agencies and for-profit and not-for-profit stakeholders. The comments will be important factors in finalizing the document and thereby shaping NHLBI's Institute-solicited future research directions.

*Privacy Act Notification Statement:* Responses to this notice are voluntary. Respondents are advised that the

Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. No proprietary, classified, confidential, or sensitive information should be included in your response. The NHLBI may use the information gathered to develop grant, contract, or other funding priorities and initiatives.

This notice is for information and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the Federal Government in general, the NIH, or the NHLBI specifically. The NHLBI does not intend to make any awards based on responses to this RFI or pay for the preparation of any information submitted or for the Government's use of such information.

Dated: January 26, 2016.

**Gary H. Gibbons,**

*Director, National Heart, Lung, and Blood Institute.*

[FR Doc. 2016-02120 Filed 2-3-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Language and Communication.

*Date:* February 22, 2016.

*Time:* 1:00 p.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Argonaut Hotel, 495 Jefferson Street, San Francisco, CA 94109.

*Contact Person:* Weijia Ni, Ph.D., Chief/Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3100, MSC 7808, Bethesda, MD 20892, (301) 594-3292, [niw@csr.nih.gov](mailto:niw@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Psychosocial Risks and Disease Prevention.

*Date:* March 1, 2016.

*Time:* 1:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Weijia Ni, Ph.D., Chief/Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3100, MSC 7808, Bethesda, MD 20892, 301-594-3292, [niw@csr.nih.gov](mailto:niw@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR Panel: Environmental Contributors to Autism Spectrum Disorders.

*Date:* March 2, 2016.

*Time:* 8:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Cambria Hotels & Suites, 1 Helen Heneghan Way, Rockville, MD 20850.

*Contact Person:* Patricia Greenwel, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2178, MSC 7818, Bethesda, MD 20892, 301-435-1169, [greenwep@csr.nih.gov](mailto:greenwep@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Fellowships: Sensory and Motor Neurosciences, Cognition and Perception.

*Date:* March 3-4, 2016.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Pier 2620 Hotel Fisherman's Wharf, 2620 Jones Street, San Francisco, CA 94133.

*Contact Person:* Sharon S Low, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7846, Bethesda, MD 20892, 301-237-1487, [lowss@csr.nih.gov](mailto:lowss@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Fellowships: Biochemistry and Biophysical Chemistry.

*Date:* March 3-4, 2016.

*Time:* 8:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* David R Jollie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4166, MSC 7806, Bethesda, MD 20892, (301)-437-7927, [jollieda@csr.nih.gov](mailto:jollieda@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Research Project Grant.

*Date:* March 3, 2016.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

*Contact Person:* Ping Wu, Ph.D., Scientific Review Officer, HDM IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3166, Bethesda, MD 20892, 301-451-8428, [wup4@csr.nih.gov](mailto:wup4@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 29, 2016.

**Carolyn Baum,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-02053 Filed 2-3-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Arthritis and Musculoskeletal and Skin Diseases Initial Review Group Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee.

*Date:* February 25-26, 2016.

*Time:* 7:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Rd. NW, Washington, DC 20015.

*Contact Person:* Helen Lin, Ph.D., Scientific Review Officer, NIH/NIAMS/RB, 6701 Democracy Blvd., Suite 800, Plaza One, Bethesda, MD 20817, 301-594-4952, [linh1@mail.nih.gov](mailto:linh1@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)